ReviewMolecular diversity2026
Pyrazole in drug development: a medicinal-chemistry based analysis of USFDA-approved drugs in last decade.
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pyrene-linked heterocyclic pyrazoles: Synthesis, antimicrobial screening, and in silico molecular insights.Smart molecules : open access · 2026Article
- Design, Synthesis, Spectral, Structural Analysis, and Biological Evaluation of Novel Pyrazole Derivatives as Anti-Tumor, Antimicrobial, and Anti-Biofilm Agents.Antibiotics (Basel, Switzerland) · 2026Article
- Green microwave synthesis of pyrazole chalcone molecular hybrids efficient route to advanced diabetes therapeutics with DNA intercalative properties.RSC advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among the diversity of existing heterocycles, nitrogen-containing heterocycles, i.e., azaheterocycles, are the most popular entity in drug discovery. In the present review, we have focused on the structural diversity of pyrazole in drug discovery and the critical analysis of approved drugs bearing this versatile pharmacophore in the past decade (2014-2023). The investigation of the USFDA-approved drug-bearing pyrazole scaffold revealed that a total of 20 drugs were approved during the period of analysis. The bifurcation of approved drugs led us to conclude that nine drugs (45%) were to treat cancer, followed by four drugs for rare genetic diseases, three for treating infection, two for neurological conditions, and one for rheumatoid arthritis and glaucoma, respectively. The investigation also revealed that the majority of drugs (65%) were indicated to be used in rare forms of cancer and diseases. Besides this, the review also highlighted that 53% of approved drugs were launched in tablet form, and 80% of these drugs were intended to be given by oral route. The drug metabolism analysis revealed that 25% of approved drugs undergo Phase 1 metabolism via CYP3A4, followed by the combined involvement of CYP3A4 and CYP2C9 for 10% of approved drugs. The drugs are chiefly excreted via the fecal route (12) and the urine (7). The structural diversity revealed that the majority of pyrazole drugs comprised a pyridine ring (7) in conjugation. At the same time, fluorine was the key halogen substituent, and amine was the major non-halogenated substituent in the approved drugs. The review is, therefore, a congregated effort to not only compile and update the USFDA-approved drugs containing pyrazole but also explore their in-depth medicinal chemistry-based analysis to enrich the medicinal chemist and allied sciences researchers for their comprehensive read.
Indexed as
Identifiers
40549292What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.